<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02682680</url>
  </required_header>
  <id_info>
    <org_study_id>GOAL RCT</org_study_id>
    <nct_id>NCT02682680</nct_id>
  </id_info>
  <brief_title>Randomized Trial Comparing Colesevelam vs. Ezetimibe</brief_title>
  <acronym>GOAL-RCT</acronym>
  <official_title>Goal Achievement of A1c and LDL in a Randomized Trial Comparing Colesevelam vs. Ezetimibe as Add-on to Baseline Statin Therapy: The GOAL-RCT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMC Diabetes &amp; Endocrinology Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LMC Diabetes &amp; Endocrinology Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 24-week, randomized, open-label study investigating the efficacy, safety and tolerability
      of colesevelam 3.75 g daily compared to ezetimibe 10 mg daily, as an add-on to baseline
      statin therapy in patients with type 2 diabetes mellitus (T2DM) who are not at target for
      glycated hemoglobin (HbA1c) (&gt; 7.0%) and low-density lipoprotein (LDL) cholesterol (&gt; 2.0
      mmol/L).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll 440 adult patients with T2DM who are not at target for HbA1c and LDL
      cholesterol. Patients who are on baseline statin therapy will be randomly assigned in a 1:1
      ratio to colesevelam 3.75 g daily for 24 weeks, or ezetimibe 10 mg daily for 24 weeks. If
      patient has statin intolerance, they may be on a fibrate and/or niacin, or on no lipid
      lowering therapy. The primary efficacy objectives are

        1. to demonstrate that colesevelam 3.75 g daily is non-inferior to ezetimibe 10 mg daily as
           add-on to statin therapy for patients achieving a composite target of HbA1c (≤ 7.0%) and
           LDL cholesterol (≤ 2.0 mmol/L) at week 24, and

        2. to compare the proportion of patients achieving a composite target of HbA1c (≤ 7.0%) and
           LDL cholesterol (≤ 2.0 mmol/L) at week 24.

      This study will also assess the primary composite outcome in a sub-group of patients on
      sodium/glucose cotransporter 2 inhibitor (SGLT2i) therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve target HbA1c and LDL cholesterol</measure>
    <time_frame>24 weeks</time_frame>
    <description>target HbA1c: ≤ 7.0%; target LDL cholesterol: ≤ 2.0 mmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve the primary outcome measure in the sub-group of subjects on sodium/glucose cotransporter 2 inhibitor (SGLT2i) therapy</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL cholesterol</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in non-high-density lipoprotein (HDL) cholesterol</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in fasting plasma glucose (FPG)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HbA1c</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL cholesterol in sub-group of subjects on SGLT2i therapy</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HDL cholesterol in sub-group of subjects on SGLT2i therapy</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in FPG in sub-group of subjects on SGLT2i therapy</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HbA1c in sub-group of subjects on SGLT2i therapy</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a composite target of glycemic control, LDL cholesterol control and blood pressure control</measure>
    <time_frame>24 weeks</time_frame>
    <description>glycemic control: A1c ≤ 7.0%; LDL cholesterol control: ≤ 2.0 mmol/L; blood pressure control: ≤ 130/80 mm Hg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a composite target of glycemic control with no hypoglycemia and no weight gain</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 0.3% reduction in HbA1c and ≥ 10% reduction in LDL cholesterol from baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 0.5% reduction in HbA1c and ≥ 15% reduction in LDL cholesterol</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in high-sensitivity C-reactive protein (hs-CRP) levels from baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in triglyceride levels from baseline</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving target HbA1c and LDL cholesterol in the sub-group of subjects on non-insulin therapies</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in FPG in the sub-group of subjects on non-insulin therapies</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HbA1c in the sub-group of subjects on non-insulin therapies</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in LDL cholesterol in the sub-group of subjects on non-insulin therapies</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in non-HDL cholesterol in the sub-group of subjects on non-insulin therapies</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-severe and severe hypoglycemia</measure>
    <time_frame>24 weeks</time_frame>
    <description>Severe hypoglycemia is defined as hypoglycemia requiring third party intervention of another person to actively administer carbohydrate, glucagon or other resuscitative actions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in alanine aminotransferase (ALT)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in creatine kinase (CK)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in body weight</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in body mass index (BMI)</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effect of colesevelam versus ezetimibe on the increased LDL cholesterol levels typically observed with initiation of SGLT2i therapy</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Persistence of therapy of colesevelam versus ezetimibe</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Persistence of therapy of colesevelam versus ezetimibe in the sub-group of subjects on SGLT2i therapy</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>LDL cholesterol reduction in patients with documented statin intolerance</measure>
    <time_frame>24 weeks</time_frame>
    <description>Statin intolerance is defined as a history of being unable to tolerate two different statins due to allergic reactions or adverse events, or have experienced a severe adverse effect with one statin</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean dose of colesevelam</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colesevelam 3.75 g daily (tablets or oral suspension) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ezetimibe 10 mg once daily for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>Colesevelam 3.75 g daily for 24 weeks</description>
    <arm_group_label>Colesevelam</arm_group_label>
    <other_name>Lodalis</other_name>
    <other_name>Welchol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Ezetimibe 10 mg daily for 24 weeks</description>
    <arm_group_label>Ezetimibe</arm_group_label>
    <other_name>Ezetrol</other_name>
    <other_name>Zetia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of type 2 diabetes &gt; 6 months

          2. HbA1c level between 7.1 to 10.0% (inclusive) within three months of study enrollment

          3. LDL cholesterol &gt; 2.0 mmol/L within three months of study enrollment

          4. Receiving a stable dose of statin for a minimum of three months, which the
             investigator does not plan to change over the 24-week trial period. If patient has
             documented statin intolerance, may be on a fibrate and/or niacin, or on no lipid
             lowering therapy

          5. Stable diabetes medications for previous three months (apart from adjustment of
             insulin dose)

          6. Informed consent

        Exclusion Criteria:

          1. Use of a second lipid lowering therapy other than statin within three months of study
             enrolment, unless on a fibrate and/or niacin if patient has statin intolerance

          2. Triglycerides ≥ 5.0 mmol/L or incalculable LDL cholesterol

          3. Significant liver enzyme or CK elevation defined as CK or ALT ≥ 3x upper limit of
             normal (ULN)

          4. Thyroid stimulating hormone (TSH) ≥ 5.0 milli-international units per litre (mIU/L) or
             actively using thyroid hormone replacement therapy

          5. Pregnant or breast feeding or planning to become pregnant or breast feed during the
             study

          6. Chronic kidney disease (CKD) stage ≥4 or estimated glomerular filtration rate (eGFR) &lt;
             30 ml/min/1.73 m-squared

          7. Severe gastroparesis or history of significant bowel resection

          8. Current use of any Investigational Product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harpreet Bajaj, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMC Diabetes &amp; Endocrinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harpreet Bajaj, MBBS, MPH</last_name>
    <phone>905-595-0560</phone>
    <email>bramptonresearch@LMC.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>LMC Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Akshay Jain, MD</last_name>
      <phone>403-288-3224</phone>
      <email>calgaryresearch@lmc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Barrie</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hani Alasaad, MBBS</last_name>
      <phone>705-737-0830</phone>
      <email>barrieresearch@lmc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Brampton</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6S 0C9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harpreet Bajaj, MBBS, MPH</last_name>
      <phone>905-595-0560</phone>
      <email>bramptonresearch@lmc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Etobicoke</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasnain Khandwala, MBBS</last_name>
      <phone>416-645-1035</phone>
      <email>etobicokeresearch@lmc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Markham</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Gupta, MBBS, MPH</last_name>
      <phone>905-294-0800</phone>
      <email>markhamresearch@lmc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Oakville</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Twum-Barima, MB ChB, MSc</last_name>
      <phone>905-337-0040</phone>
      <email>oakvilleresearch@lmc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Thornhill</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Goldenberg, MD</last_name>
      <phone>905-763-8660</phone>
      <email>thornhillresearch@lmc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LMC Bayview</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronnie Aronson, MD</last_name>
      <phone>416-645-2929</phone>
      <email>torontoresearch@lmc.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>February 10, 2016</last_update_submitted>
  <last_update_submitted_qc>February 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMC Diabetes &amp; Endocrinology Ltd.</investigator_affiliation>
    <investigator_full_name>Dr. Harpreet Bajaj</investigator_full_name>
    <investigator_title>Endocrinologist</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>hyperlipidaemia</keyword>
  <keyword>colesevelam</keyword>
  <keyword>ezetimibe</keyword>
  <keyword>LDL cholesterol</keyword>
  <keyword>glycated hemoglobin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

